Involvement of 5-lipoxygenase in Alzheimer's disease: A role for DNA methylation

Journal of Alzheimer's Disease

Volumn 37, Issue 1, 2013, Pages 3-8

  Di Francesco, Andrea ^a   Arosio, Beatrice ^b,c   Gussago, Cristina ^b   Dainese, Enrico ^a,d   Mari, Daniela ^b,c   D'Addario, Claudio ^a   MacCarrone, Mauro ^d,e  

^a UNIVERSITY OF TERAMO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

5 lipoxygenase; Alzheimer's disease; biomarker; DNA methylation; fatty acid amide hydrolase; peripheral blood mononuclear cells

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BIOLOGICAL MARKER; LEUKOTRIENE B4; PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; NERVE DEGENERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARACHIDONATE 5-LIPOXYGENASE; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE;

EID: 84883142421     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130506     Document Type: Article

References (48)

1. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222.
2. Pratic̀o D (2008) Oxidative stress hypothesis in Alzheimer's disease: A reappraisal. Trends Pharmacol Sci 29, 609-615.
3. Glass CK, Saijo K,Winner B, MarchettoMC,GageFH(2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
4. Kuhn H, Saam J, Eibach S, Holzhutter HG, Ivanov I,Walther M (2005) Structural biology of mammalian lipoxygenases: Enzymatic consequences of targeted alterations of the protein structure. Biochem Biophys Res Commun 338, 93-101. (Pubitemid 41540542)
5. Haeggstr̈om JZ, Funk CD (2011) Lipoxygenase and leukotriene pathways: Biochemistry, biology, and roles in disease. Chem Rev 111, 5866-5898.
6. Sugaya K, Uz T, Kumar V, Manev H (2000) New antiinflammatory treatment strategy in Alzheimer's disease. Jpn J Pharmacol 82, 85-94. (Pubitemid 30153588)
7. Klegeris A, McGeer PL (2002) Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 23, 787-794. (Pubitemid 35217703)
8. Chu J, Li JG, Ceballos-Diaz C, Golde T, Pratic̀o D (2013) The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: In vivo and in vitro evidence. Biol Psychiatry. doi: 10.1016/j.biopsych.2012.12.012
9. R°admark O, Werz O, Steinhilber D, Samuelsson B (2007) 5-Lipoxygenase: Regulation of expression and enzyme activity. Trends Biochem Sci 32, 332-341. (Pubitemid 47021417)
10. Phillis JW, Horrocks LA, Farooqui AA (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: Their role and involvement in neurological disorders. Brain Res Rev 52, 201-243. (Pubitemid 44291802)
11. Manev H, Chen H, Dzitoyeva S, Manev R (2011) Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 35, 315-319.
12. Manev H, Uz T, Sukaya K, Sugaya K, Qu T (2000) Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J 14, 1464-1469. (Pubitemid 30439756)
13. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, Budka H (2002) A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol 104, 601-607. (Pubitemid 36075425)
14. Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ (2006) Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 26, 99-106.
15. Chinnici CM, Yao Y, Pratic̀o D (2007) The 5-lipoxygenase enzymatic pathway in the mouse brain: young versus old. Neurobiol Aging 28, 1457-1462. (Pubitemid 47081230)
16. Lammers CH, Schweitzer P, Facchinetti P, Arrang JM, Madamba SG, Siggins GR, Piomelli D (1996) Arachidonate 5-lipoxygenase and its activating protein: Prominent hippocampal expression and role in somatostatin signaling. J Neurochem 66, 147-152. (Pubitemid 26010775)
17. UzT, Pesold C, Longone P, ManevH(1998) Aging-associated up-regulation of neuronal 5-lipoxygenase expression: Putative role in neuronal vulnerability. FASEB J 12, 439-449. (Pubitemid 28146523)
18. Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratic̀o D (2008) 5-Lipoxygenase gene disruption reduces Amyloid-pathology in a mouse model of Alzheimer's disease. FASEB J 22, 1169-1178. (Pubitemid 351519971)
19. Centonze D, Battistini L, Maccarrone M (2008) The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Curr Pharm Des 14, 2370-2382.
20. Chomczynski P, Sacchi N (2006) The single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction: Twenty-something years on. Nat Protoc 1, 581-585.
21. Miller SA, Dykes DD, PoleskyHF (1988)Asimple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215.
22. D'Addario C, Dell'osso B, Palazzo MC, Benatti B, Lietti L, Cattaneo E, Galimberti D, Fenoglio C, Cortini F, Scarpini E, Arosio B, Di Francesco A, Di Benedetto M, Romualdi P, Candeletti S, Mari D, Bergamaschini L, Bresolin N, Maccarrone M, AltamuraAC(2012) SelectiveDNAmethylation ofBDNF promoter in bipolar disorder: Differences among patients with BDI and BDII. Neuropsychopharmacology 37, 1647-1655.
23. List̀ F, Caruso C, Lio D, Colonna-Romano G, Chiappelli M, Licastro F, Candore G (2010) Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from northern Italy: Implication for pharmacogenomics. J Alzheimers Dis 19, 551-557.
24. Qu T, Manev R, Manev H (2001) 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and lateonset Alzheimer's disease. J Neuropsychiatry Clin Neurosci 13, 304-305. (Pubitemid 32499684)
25. Alvarez V, Gonźalez P, Corao AI, Meńendez M, Lahoz CH, Mart́nez C, Calatayud M, Morales B, Coto E (2008) The Sp1/Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene promoter is not associated with late onset Alzheimer disease. Alzheimer Dis Assoc Disord 22, 177-180.
26. Zhang Z, Chen CQ, Manev H (2004) DNA methylation as an epigenetic regulator of neural 5-lipoxygenase expression: Evidence in human NT2 and NT2-N cells. J Neurochem 88, 1424-1430. (Pubitemid 38366918)
27. Katryniok C, Schnur N, Gillis A, von Knethen A, Sorg BL, Looijenga L, R°admark O, Steinhilber D (2010) Role of DNA methylation and methyl-DNA binding proteins in the repression of 5-lipoxygenase promoter activity. Biochim Biophys Acta 1801, 49-57.
28. Gr̈aff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222-226.
29. Copped̀e F, Migliore L (2010) Evidence linking genetics, environment, and epigenetics to impaired DNA repair in Alzheimer's disease. J Alzheimers Dis 20, 953-966.
30. Bakulski KM, Dolinoy DC, Sartor MA, Paulson HL, Konen JR, Lieberman AP, Albin RL, Hu H, Rozek LS (2012) Genome-wide DNA methylation differences between lateonset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis 29, 571-588.
31. Salomone S, Caraci F, Leggio GM, Fedotova J, Drago F (2012) New pharmacological strategies for treatment of Alzheimer's disease: Focus on disease modifying drugs. Br J Clin Pharmacol 73, 504-517.
32. Dangond F, Gullans SR (1998) Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by trichostatin A and butyrate. Biochem Biophys Res Commun 247, 833-837. (Pubitemid 28418477)
33. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J 370, 737-749. (Pubitemid 36399066)
34. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D (2002) The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 277, 4374-4379. (Pubitemid 34975655)
35. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D (2003) DNA methylation regulates 5-lipoxygenase promoter activity. Adv Exp Med Biol 525, 169-172. (Pubitemid 36667726)
36. Imbesi M, Dzitoyeva S, Ng LW, Manev H (2009) 5-Lipoxygenase and epigenetic DNA methylation in aging cultures of cerebellar granule cells. Neuroscience 164, 1531-1537.
37. Dzitoyeva S, Imbesi M, Ng LW, Manev H (2009) 5-lipoxygenase DNA methylation and mRNA content in the brain and heart of young and old mice. Neural Plas 2009, 209-596.
38. Arosio B, Bulbarelli A, Bastias Candia S, Lonati E, Mastronardi L, Romualdi P, Candeletti S, Gussago C, Galimberti D, Scarpini E, Dell'Osso B, Altamura C, MacCarrone M, Bergamaschini L, D'Addario C, Mari D (2012) Pin1 contribution to Alzheimer's disease: Transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. Neurodegener Dis 10, 207-211.
39. D'Addario C, Di Francesco A, Arosio B, Gussago C, Dell'Osso B, Bari M, Galimberti D, Scarpini E, Altamura AC, Mari D, Maccarrone M (2012) Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease. PLoS One 7, e39186.
40. Murphy N, Cowley TR, Blau CW, Dempsey CN, Noonan J, Gowran A, Tanveer R, Olango WM, Finn DP, Campbell VA, Lynch MA (2012) The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J Neuroinflammation 9, 79-90.
41. Van der Stelt M, van Kuik JA, Bari M, van Zadelhoff G, Leeflang BR, Veldink GA, Finazzi-Agr̀o A, Vliegenthart JF, Maccarrone M (2002) Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: Conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45, 3709-3720. (Pubitemid 34856111)
42. Rouzer CA, Marnett LJ (2011) Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: Cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev 111, 5899-5921.
43. Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang YP, Teng Z, Chen C (2012) Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep 2, 1329-1339.
44. Piro JR, Benjamin DI, Duerr JM, PiY, Gonzales C,WoodKM, Schwartz JW, Nomura DK, Samad TA (2012) A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep 1, 617-623.
45. Cunningham C, Skelly DT (2012) Non-steroidal antiinflammatory drugs and cognitive function: Are prostaglandins at the heart of cognitive impairment in dementia and delirium? J Neuroimmune Pharmacol 7, 60-73.
46. Imbimbo BP, Solfrizzi V, Panza F (2010) Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci. doi: 10.3389/fnagi.2010.00019
47. Ng SC, Chan FK (2010) NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol 26, 611-617.
48. Vikman S, Brena RM, Armstrong P, Hartiala J, Stephensen CB, Allayee H (2009) Functional analysis of 5-lipoxygenase promoter repeat variants. Hum Mol Genet 18, 4521-4529.